Nixon Peabody Trust Co. Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nixon Peabody Trust Co. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,293 shares of the biopharmaceutical company’s stock after buying an additional 43 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Alnylam Pharmaceuticals were worth $540,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after buying an additional 16,756 shares during the last quarter. Swiss National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after buying an additional 1,000 shares during the last quarter. Eagle Asset Management Inc. lifted its position in Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after purchasing an additional 8,462 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $246.75 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market capitalization of $31.94 billion, a P/E ratio of -113.71 and a beta of 0.35. The company has a 50 day moving average price of $254.30 and a 200 day moving average price of $262.42. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ALNY shares. Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Raymond James upped their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Scotiabank reduced their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $304.26.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.